Irina Asherova
Overview
Explore the profile of Irina Asherova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Colombo C, Ramm G, Lindblad A, Corti F, Porcaro L, Alghisi F, et al.
J Cyst Fibros
. 2023 Feb;
22(2):263-265.
PMID: 36739240
Cystic-fibrosis-related liver disease (CFLD) is a variable phenotype of CF. The severe CFLD variant with cirrhosis or portal hypertension has a poor prognosis and life expectancy. CFTR modulator therapies are...
2.
Kondratyeva E, Bulatenko N, Melyanovskaya Y, Efremova A, Zhekaite E, Sherman V, et al.
Curr Issues Mol Biol
. 2022 Oct;
44(10):5126-5138.
PMID: 36286063
The presence of complex alleles in the CFTR gene can lead to difficulties in diagnosing cystic fibrosis and cause resistance to therapy with CFTR modulators. Tezacaftor/ivacaftor therapy for 8 months...
3.
Colombo C, Alicandro G, Oliver M, Lewindon P, Ramm G, Ooi C, et al.
J Cyst Fibros
. 2021 Apr;
21(2):220-226.
PMID: 33814323
Background: The efficacy and safety of ursodeoxycholic acid (UDCA) for the treatment of liver disease associated with cystic fibrosis (CF) are under discussion, and clinical practice varies among centers. The...
4.
Ratjen F, Moeller A, McKinney M, Asherova I, Alon N, Maykut R, et al.
J Cyst Fibros
. 2018 Apr;
18(1):78-85.
PMID: 29685813
Objective: Antibiotic eradication treatment is the standard-of-care for cystic fibrosis (CF) patients with early Pseudomonas aeruginosa (Pa)-infection; however, evidence from placebo-controlled trials is limited. Methods: This double-blind, placebo-controlled trial randomised...